The use of remdesivir outside of clinical trials during the COVID-19 pandemic
Abstract With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and...
Main Authors: | Vesa Halimi, Armond Daci, Nevenka Ridova, Irina Panovska-Stavridis, Milena Stevanovic, Venko Filipce, Aleksandar Dimovski, Aleksandra Grozdanova |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Journal of Pharmaceutical Policy and Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40545-020-00258-8 |
Similar Items
-
Current regulatory approaches for accessing potential COVID-19 therapies
by: Vesa Halimi, et al.
Published: (2020-05-01) -
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
by: Chih-Jen Yang, et al.
Published: (2021-02-01) -
Critical reappraisal of remdesivir investigational trials in COVID-19
by: P. Brouqui, et al.
Published: (2020-11-01) -
Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections
by: S. Saqrane, et al.
Published: (2021-05-01) -
Remdesivir: Mechanism and Effectiveness for Coronavirus Disease 2019 (COVID-19)
by: Vina Neldi, et al.
Published: (2020-07-01)